Raùl P. L.
- Country
- Spain
- Department
- Hematology and Hemotherapy
Research Overview
- Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Phase 3 Study of BGB-11417 plus Zanubrutinib versus Venetoclax plus Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
Data & Insights
Has run more than one trial at 108 of 272 partner sites.
Specializations
Myeloid Disorders
The investigator specializes in treating various myeloid neoplasms, with particular focus on myelofibrosis and conditions involving moderate thrombocytopenia.
- Myelofibrosis Management
- JAK Inhibitor-naïve Treatment Approaches
- Advanced Myeloid Neoplasms
Their work extends to innovative therapeutic combinations for treatment-naïve myelofibrosis patients.
Chronic Leukemias
The investigator focuses on treating chronic lymphocytic leukemia (CLL) and BCR-ABL1+ chronic myeloid leukemia, exploring various therapeutic strategies.
- CLL/SLL Treatment Optimization
- Targeted Therapy Approaches
- Molecular Response Assessment
Their expertise includes evaluation of novel therapeutic combinations and treatment duration optimization.
Novel Therapeutic Applications
The investigator explores selective inhibitors and innovative drug combinations for hematologic malignancies.
- Nuclear Export Inhibition
- Tyrosine Kinase Inhibitor Therapy
- Combination Treatment Strategies
Their research encompasses both single-agent and combination approaches in hematologic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.